Today’s presentation at CTAD, a leading international Alzheimer's conference, expands research supporting the value of ultra-low-field MRI in monitoring amyloid-related imaging abnormalities (ARIA).

Portable ultra-low-field MR brain imaging provides affordable and accessible technology that may help physicians monitor ARIA and Alzheimer's disease progression in diverse professional care settings.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and ...

The Mizzou Point-of-Care Assessment System, or MPASS, tests a person's motor ability through three activities: standing still, walking, and standing up from a bench, all while counting backwards in ...

The brain has a waste-disposal system that clears away junk proteins that contribute to the development of dementia and Alzheimer's disease, a new study finds. Advanced imaging scans have revealed a ...

Hyperfine Swoop® AI-Powered Portable MRI System Demonstrates 100% Sensitivity for ARIA-E Detection in New Data Presented at the 2025 Alzheimer’s Association International Conference Interim results ...